HCP 12
Breast Cancer Specialist · Spain · Consultant
Illustrative synthetic data for prototype demonstration — not real clinical findings.
Discussion summary
Sceptical of incremental benefit; prefers to wait for longer follow-up and mature data.
Key themes
Pre / post perception
Overall perception shiftPre-congress vs post-congress
5 improved
Perception of clinical efficacy
Confidence in the evidence
Safety / tolerability perception
Likelihood to prescribe
Familiarity with treatment
Competitive perception
Illustrative synthetic measures. Movement is shown as an observed pre/post shift, not a causal effect of the congress.
KBQs discussed
Position against each predefined questionClinical significance of the primary endpoint
What is the expert consensus regarding the clinical significance of the study’s primary endpoint results?
“For now I would stay with our established pathway until the data are more mature.”
Safety, tolerability and willingness to prescribe
How do HCP perceptions of the trial’s safety and tolerability profile impact their willingness to adopt and prescribe the treatment?
“The trade-off gives me pause — I am not sure the tolerability justifies it for many of my patients.”
Use in node-positive populations
What is the clinical consensus among HCPs regarding the use of CDK4/6 inhibitors in node-positive patient populations?
Sequencing after adjuvant recurrence
How do clinicians approach treatment sequencing following recurrence on an adjuvant CDK4/6 inhibitor?
“Progression on the class tells me the mechanism is exhausted — I switch rather than persist.”
Compelling nature of the primary endpoint
How compelling are the primary endpoint findings in driving prospective prescribers to select this treatment over existing options?
“The effect is real but not large enough to change what I reach for first.”
Perception of safety and tolerability
How do experts perceive the safety and tolerability profile demonstrated in the trial?
“The cumulative monitoring burden in a routine clinic worries me.”